These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 30285585)

  • 1. Predictive factors for radiographic progression of large joint damage in patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs (bDMARDs): Results of 3 to 4 years of follow-up.
    Nakajima A; Terayama K; Sonobe M; Aoki Y; Takahashi H; Akatsu Y; Taniguchi S; Yamada M; Kubota A; Nakagawa K
    Mod Rheumatol; 2019 Nov; 29(6):903-909. PubMed ID: 30285585
    [No Abstract]   [Full Text] [Related]  

  • 2. Health assessment questionnaire-disability index (HAQ-DI) score at the start of biological disease-modifying antirheumatic drug (bDMARD) therapy is associated with radiographic progression of large joint damage in patients with rheumatoid arthritis.
    Nakajima A; Aoki Y; Terayama K; Sonobe M; Takahashi H; Saito M; Nakagawa K
    Mod Rheumatol; 2017 Nov; 27(6):967-972. PubMed ID: 28271947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiographic progression of large joint damage in patients with rheumatoid arthritis treated with biological disease-modifying anti-rheumatic drugs.
    Nakajima A; Aoki Y; Sonobe M; Takahashi H; Saito M; Terayama K; Nakagawa K
    Mod Rheumatol; 2016 Jul; 26(4):517-21. PubMed ID: 26473376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiographic changes and factors associated with subsequent progression of damage in weight-bearing joints of patients with rheumatoid arthritis under TNF-blocking therapies-three-year observational study.
    Matsushita I; Motomura H; Seki E; Kimura T
    Mod Rheumatol; 2017 Jul; 27(4):570-575. PubMed ID: 27589926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
    Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
    Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis.
    Henaux S; Ruyssen-Witrand A; Cantagrel A; Barnetche T; Fautrel B; Filippi N; Lukas C; Raffeiner B; Rossini M; Degboé Y; Constantin A
    Ann Rheum Dis; 2018 Apr; 77(4):515-522. PubMed ID: 29187350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of healthcare resources in a cohort of rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs or tofacitinib.
    Machado-Alba JE; Machado-Duque ME; Gaviria-Mendoza A; Reyes JM; Gamboa NC
    Clin Rheumatol; 2021 Apr; 40(4):1273-1281. PubMed ID: 32997316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission with Six Months of Biological DMARDs Treatment.
    Miwa Y; Takahashi R; Ikari Y; Maeoka A; Nishimi S; Oguro N; Hayashi T; Hatano M; Isojima S; Yanai R; Kasama T; Toyoshima Y; Inagaki K; Sanada K
    Intern Med; 2017; 56(8):903-906. PubMed ID: 28420837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence of rheumatoid arthritis patients to biologic disease-modifying antirheumatic drugs: a cross-sectional study.
    Mena-Vazquez N; Manrique-Arija S; Yunquera-Romero L; Ureña-Garnica I; Rojas-Gimenez M; Domic C; Jimenez-Nuñez FG; Fernandez-Nebro A
    Rheumatol Int; 2017 Oct; 37(10):1709-1718. PubMed ID: 28631046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
    Ciubotariu E; Gabay C; Finckh A;
    J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do radiographic joint damage and disease activity influence functional disability through different mechanisms? Direct and indirect effects of disease activity in established rheumatoid arthritis.
    Nair SC; Bijlsma JW; van der Werf JH; van der Veen MJ; Linn-Rasker SP; Vreugdenhil S; Lafeber FP; Welsing PM
    J Rheumatol; 2013 Sep; 40(9):1505-12. PubMed ID: 23818710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive factors associated with the progression of large-joint destruction in patients with rheumatoid arthritis after biologic therapy: A post-hoc analysis using FDG-PET/CT and the ARASHI (assessment of rheumatoid arthritis by scoring of large-joint destruction and healing in radiographic imaging) scoring method.
    Suto T; Yonemoto Y; Okamura K; Okura C; Kaneko T; Kobayashi T; Tachibana M; Tsushima Y; Takagishi K
    Mod Rheumatol; 2017 Sep; 27(5):820-827. PubMed ID: 27919199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiological progression in early rheumatoid arthritis after DMARDS: a one-year follow-up study in a clinical setting.
    Sanmarti R; Gomez A; Ercilla G; Gratacos J; Larrosa M; Suris X; Vinas O; Salvador G; Munoz-Gomez J; Canete JD
    Rheumatology (Oxford); 2003 Sep; 42(9):1044-9. PubMed ID: 12730518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Factors Toward Clinically Relevant Radiographic Progression in Patients With Rheumatoid Arthritis in Clinical Practice: A Japanese Multicenter, Prospective Longitudinal Cohort Study for Achieving a Treat-to-Target Strategy.
    Koga T; Okada A; Fukuda T; Hidaka T; Ishii T; Ueki Y; Kodera T; Nakashima M; Takahashi Y; Honda S; Horai Y; Watanabe R; Okuno H; Aramaki T; Izumiyama T; Takai O; Miyashita T; Sato S; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Origuchi T; Nakamura H; Aoyagi K; Eguchi K; Kawakami A;
    Medicine (Baltimore); 2016 Apr; 95(17):e3476. PubMed ID: 27124044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive factors of 5-year health assessment questionnaire disability in early rheumatoid arthritis.
    Combe B; Cantagrel A; Goupille P; Bozonnat MC; Sibilia J; Eliaou JF; Meyer O; Sany J; Dubois A; Daurès JP; Dougados M
    J Rheumatol; 2003 Nov; 30(11):2344-9. PubMed ID: 14677175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Large-joint damage in patients with early rheumatoid arthritis and its association with treatment strategy and damage of the small joints.
    Dirven L; van den Broek M; Kroon HM; Grillet BA; Han KH; Kerstens PJ; Huizinga TW; Lems WF; Allaart CF
    Rheumatology (Oxford); 2012 Dec; 51(12):2262-8. PubMed ID: 22942403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doppler ultrasound predicts successful discontinuation of biological DMARDs in rheumatoid arthritis patients in clinical remission.
    Terslev L; Brahe CH; Hetland ML; Georgiadis S; Ellegaard K; Juul L; Huynh T; Døhn UM; Fana V; Møller T; Krabbe S; Ørnbjerg LM; Glinatsi D; Røgind H; Hansen A; Nørregaard J; Jacobsen S; Jensen DV; Manilo N; Asmussen K; Boesen M; Rastiemadabadi Z; Morsel-Carlsen L; Møller JM; Krogh NS; Østergaard M
    Rheumatology (Oxford); 2021 Dec; 60(12):5549-5559. PubMed ID: 33748831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Magnetic Resonance Imaging vs Conventional Treat-to-Target Strategies on Disease Activity Remission and Radiographic Progression in Rheumatoid Arthritis: The IMAGINE-RA Randomized Clinical Trial.
    Møller-Bisgaard S; Hørslev-Petersen K; Ejbjerg B; Hetland ML; Ørnbjerg LM; Glinatsi D; Møller J; Boesen M; Christensen R; Stengaard-Pedersen K; Madsen OR; Jensen B; Villadsen JA; Hauge EM; Bennett P; Hendricks O; Asmussen K; Kowalski M; Lindegaard H; Nielsen SM; Bliddal H; Krogh NS; Ellingsen T; Nielsen AH; Balding L; Jurik AG; Thomsen HS; Østergaard M
    JAMA; 2019 Feb; 321(5):461-472. PubMed ID: 30721294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug.
    Kielhorn A; Porter D; Diamantopoulos A; Lewis G
    Curr Med Res Opin; 2008 Sep; 24(9):2639-50. PubMed ID: 18687164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decrease in bone mineral density during three months after diagnosis of early rheumatoid arthritis measured by digital X-ray radiogrammetry predicts radiographic joint damage after one year.
    Ziegelasch M; Forslind K; Skogh T; Riklund K; Kastbom A; Berglin E
    Arthritis Res Ther; 2017 Sep; 19(1):195. PubMed ID: 28865482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.